Navigation Links
Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
Date:12/10/2012

CRi),
  • The median duration of CRc was 7.0,weeks, which was likely impacted by a high percentage (37 percent) of patients who were bridged to a HSCT,
  • An additional 16 percent of patients achieved a PR,
  • Of those refractory to their last AML therapy, 48 percent achieved at least a PR with quizartinib,
  • The rate of HSCT after quizartinib use was 37 percent, which represents clinical benefit in this heavily pretreated patient population,  
  • The median overall survival was 25.6 weeks,
  • Ten patients (26 percent) are considered "long-term survivors" given they remained alive for more than 12 months
  • The most common treatment-emergent AEs were nausea (53 percent), vomiting (41 percent), febrile neutropenia (38 percent), diarrhea (37 percent), anemia (34 percent), QT interval prolongation (27 percent) and fatigue (24 percent).  QT interval prolongations were asymptomatic, transient, and there were no Grade 4 events or deaths associated with QT prolongation. A total of 25 patients (18 percent) experienced an AE resulting in discontinuation of quizartinib, with the most common AE leading to discontinuation being progressive disease.
  • Overall, responses (CRc) were achieved in 46 percent of heavily pretreated patients with the FLT3-ITD mutation. These responses are clinically meaningful given they allowed a high percentage (37 percent) of  patients to be bridged to a stem cell transplant, and 23 percent of the FLT3-ITD positive patients remained alive for more than 12 months (of which 61 percent received a HSCT). The potential impact of bridge to HSCT was shown in the median overall survival for patients with the FLT3-ITD mutation which was 33.3 weeks for those who had a subsequent HSCT, compared to 17.7 weeks in those patients with the FLT3-ITD mutation who did not receive a subsequent HSCT.  Nearly one-in-three patients without the FLT3-ITD mutation also responded to qui
    '/>"/>

  • SOURCE Ambit Biosciences
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
    2. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
    3. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
    4. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
    5. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
    6. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
    7. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
    8. Xstelos Holdings Announces Dividend
    9. Medbox, Inc. Announced Increased Funding for Corporate Giving Program in 2013
    10. Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
    11. IRIDEX Corporation Announces Preliminary Results of its Tender Offer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
    (Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
    (Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
    Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
    ... Halozyme Therapeutics, Inc. (Nasdaq: HALO ) today ... HYLENEX manufacturing and has identified a corrective action plan ... Halozyme and Baxter are finalizing the materials for a ... seek concurrence with the reintroduction strategy. During several meetings ...
    ... LONDON, Aug. 31 Following a recent analysis ... Sullivan presented Lodox Systems (Pty) Ltd (Lodox) with ... Leadership Award".  Statscan, Lodox,s digital x-ray product, stunned ... diagnostic, whole-body x-ray pictures in just 13 seconds. ...
    Cached Medicine Technology:Halozyme Provides HYLENEX® Product Reintroduction Update 2Halozyme Provides HYLENEX® Product Reintroduction Update 3Frost & Sullivan Applauds the Lodox Statscan Critical Imaging System for Outperforming All Competing Products 2Frost & Sullivan Applauds the Lodox Statscan Critical Imaging System for Outperforming All Competing Products 3Frost & Sullivan Applauds the Lodox Statscan Critical Imaging System for Outperforming All Competing Products 4
    (Date:4/17/2014)... vaccine brands for children may not be the most ... factors when choosing vaccines, driving the market toward what ... new study by University of Illinois researchers. , "The ... numerous factors," says Sheldon H. Jacobson, a co-author of ... of mathematics at the U. of I. "In an ...
    (Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
    (Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
    (Date:4/17/2014)... who treat patients with a severe and progressive ... agonizing treatment decision. , The drug sirolimus can ... shortness of breath. But some patients eventually may ... fatal complications following transplantation. , "It,s a terrible ... of Loyola University Medical Center,s LAM Clinic and ...
    (Date:4/17/2014)... IL, April 17, 2014-- Colic affects about one in ... for numerous pediatric visits during the first several months ... colic symptoms was showing promise; however, the April 1, ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics and ... L reuteri for infant colic did ...
    Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
    ... Saving Benefit Faces Eventual Elimination Without Relief , ... of President Obama,s pledge not to raise taxes on the ... outside of the normal legislative process -- adopting provisions approved ... the use of flexible spending accounts (FSAs) in order to ...
    ... from a new virtual reality training programme created at ... have been working with researchers in the School of ... scenarios that test expert players, perceptual skills. Lead ... Senior Lecturer in Visual Perception who has previously collaborated ...
    ... to educate, inform, and empower the people of Chicago, ... its 25-minute live call-in show, "Community Health," on ... at 6:00 PM on Channel 21. , ... Health Clinics with Erin Buckley, FNP-C, Certified Family Nurse ...
    ... Oct. 14 Peter Sheldon, Vice President of Operations ... commercial cleaning businesses, will be a featured speaker at ... to be held on October 14-15 at The Fairmont ... is "Be the Best in Your Business with Best ...
    ... 15, 2009 marks the 35th anniversary of the founding of ... McDonald Houses in 52 countries and regions throughout the world, ... the Philadelphia House,s two locations (on Chestnut Street, and at ... McDonald House of Southern New Jersey, the world,s 51st House, ...
    ... ... a few years ago, today it seems "Natural" is the new buzz word in retail, ... Buster was recently featured on an episode of The Dr. Oz Show in a segment ... ...
    Cached Medicine News:Health News:Fight to Preserve Flexible Spending Accounts Moves to the House of Representatives 2Health News:Fight to Preserve Flexible Spending Accounts Moves to the House of Representatives 3Health News:Increased success a 'virtual' certainty for rugby players 2Health News:Retail Health Clinics - The Real Story 2Health News:Coverall Executive Peter Sheldon To Be Featured Speaker at PRSM Mid-Year Conference 2Health News:Philadelphia-Born Ronald McDonald House(R) Program Celebrates 35 Years 2Health News:Philadelphia-Born Ronald McDonald House(R) Program Celebrates 35 Years 3Health News:Sinus Buster Paves the Way for Natural OTC Products and Mainstream Success 2
    Lambotte periosteal elevators....
    Modified Freer periosteal elevator, #163, slight curve, 21 cm....
    Williger periosteal elevator, 6 1/4", sharp, 5 mm wide....
    Alley periosteal elevator, extra long, 21 cm, 8-1/4"....
    Medicine Products: